Progress in treatment by percutaneous coronary intervention: The stent of the future;Avances en el tratamiento mediante intervención coronaria percutánea: el stent del futuro

Revista Espanola de Cardiologia

Volumn 66, Issue 6, 2013, Pages 483-496

  Muramatsu, Takashi ^a   Onuma, Yoshinobu ^a   Zhang, Yao Jun ^a   Bourantas, Christos V ^a   Kharlamov, Alexander ^a   Diletti, Roberto ^a   Farooq, Vasim ^a   Gogas, Bill D ^b   Garg, Scot ^c   García García, Hector M ^a   Ozaki, Yukio ^d   Serruys, Patrick W ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL HEALTH SERVICE   (United Kingdom)

^d FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Bioresorbable scaffold; Coronary artery disease; Drug eluting stent; Vascular reparative therapy

Indexed keywords

POLYMER;

ARTICLE; DELAYED HYPERSENSITIVITY; DRUG ELUTING STENT; ENDOTHELIAL DYSFUNCTION; PERCUTANEOUS CORONARY INTERVENTION; SAFETY; STENT THROMBOSIS; ANIMAL; GRAFT OCCLUSION; HUMAN; PROCEDURES; STENT; TRENDS;

ANIMALS; DRUG-ELUTING STENTS; GRAFT OCCLUSION, VASCULAR; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; STENTS;

EID: 84932125127     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2012.12.009     Document Type: Article

References (71)

1. A.R. Gruntzig, A. Senning, and W.E. Siegenthaler Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty N Engl J Med 301 1979 61 68 (Pubitemid 9229695)
2. U. Sigwart, J. Puel, V. Mirkovitch, F. Joffre, and L. Kappenberger Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty N Engl J Med 316 1987 701 706 (Pubitemid 17036474)
3. U. Sigwart, P. Urban, S. Golf, U. Kaufmann, C. Imbert, and A. Fischer Emergency stenting for acute occlusion after coronary balloon angioplasty Circulation 78 5 Pt 1 1988 1121 1127
4. P.W. Serruys, P. De Jaegere, F. Kiemeneij, C. Macaya, W. Rutsch, and G. Heyndrickx A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group N Engl J Med 331 1994 489 495 (Pubitemid 24256751)
5. R. Hoffmann, G.S. Mintz, G.R. Dussaillant, J.J. Popma, A.D. Pichard, and L.F. Satler Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study Circulation 94 1996 1247 1254 (Pubitemid 26307249)
6. M.C. Morice, P.W. Serruys, J.E. Sousa, J. Fajadet, E. Ban Hayashi, and M. Perin A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization N Engl J Med 346 2002 1773 1780 (Pubitemid 34586912)
7. G.W. Stone, S.G. Ellis, D.A. Cox, J. Hermiller, C. O'Shaughnessy, and J.T. Mann A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease N Engl J Med 350 2004 221 231 (Pubitemid 38067635)
8. A.J. Nordmann, M. Briel, and H.C. Bucher Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: A meta-analysis Eur Heart J 27 2006 2784 2814 (Pubitemid 44871464)
9. E. Camenzind, P.G. Steg, and W. Wijns Stent thrombosis late after implantation of first-generation drug-eluting stents: A cause for concern Circulation 115 2007 1440 1455 discussion 55 (Pubitemid 46648381)
10. M. Joner, A.V. Finn, A. Farb, E.K. Mont, F.D. Kolodgie, and E. Ladich Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk J Am Coll Cardiol 48 2006 193 202 (Pubitemid 43929240)
11. R. Virmani, G. Guagliumi, A. Farb, G. Musumeci, N. Grieco, and T. Motta Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 109 2004 701 705 (Pubitemid 38222887)
12. K. Rasmussen, M. Maeng, A. Kaltoft, P. Thayssen, H. Kelbaek, and H.H. Tilsted Efficacy and safety of zotarolimus-eluting and sirolimus-eluting coronary stents in routine clinical care (SORT OUT III): A randomised controlled superiority trial Lancet 375 2010 1090 1099
13. G.W. Stone, A. Rizvi, W. Newman, K. Mastali, J.C. Wang, and R. Caputo Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease N Engl J Med 362 2010 1663 1674
14. E. Kedhi, K.S. Joesoef, E. McFadden, J. Wassing, C. Van Mieghem, and D. Goedhart Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): A randomised trial Lancet 375 2010 201 209
15. G.G. Stefanini, B. Kalesan, P.W. Serruys, D. Heg, P. Buszman, and A. Linke Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial Lancet 378 2011 1940 1948
16. A.V. Finn, G. Nakazawa, M. Joner, F.D. Kolodgie, E.K. Mont, and H.K. Gold Vascular responses to drug eluting stents: importance of delayed healing Arterioscler Thromb Vasc Biol 27 2007 1500 1510 (Pubitemid 46986103)
17. J.M. De la Torre Hernandez, and S. Windecker Trombosis muy tardía con nuevos stents farmacoactivos: ¿ha dejado de ser un asunto relevante? Rev Esp Cardiol 65 2012 595 598
18. E. Grube, S. Sonoda, F. Ikeno, Y. Honda, S. Kar, and C. Chan Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer Circulation 109 2004 2168 2171 (Pubitemid 38625391)
19. R.A. Byrne, A. Kastrati, S. Massberg, A. Wieczorek, K.L. Laugwitz, and M. Hadamitzky Biodegradable polymer versus permanent polymer drug-eluting stents and everolimus- versus sirolimus-eluting stents in patients with coronary artery disease: 3-year outcomes from a randomized clinical trial J Am Coll Cardiol 58 2011 1325 1331
20. S. Windecker, P.W. Serruys, S. Wandel, P. Buszman, S. Trznadel, and A. Linke Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): A randomised non-inferiority trial Lancet 372 2008 1163 1173
21. P.W. Serruys, P. Buszman, A. Linke, T. Ischinger, D. Antoni, and V. Klauss TCT-44 LEADERS: 5-year follow-up from a prospective, randomized trial of biolimus A9-eluting stents with a biodegradable polymer vs. sirolimus-eluting stents with a durable polymer- final report of the LEADERS study J Am Coll Cardiol 60 2012 B13 B14
22. G.G. Stefanini, R.A. Byrne, P.W. Serruys, A. De Waha, B. Meier, and S. Massberg Biodegradable polymer drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: A pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials Eur Heart J 33 2012 1214 1222
23. I.T. Meredith, S. Verheye, C.L. Dubois, J. Dens, J. Fajadet, and D. Carrie Primary endpoint results of the EVOLVE trial: A randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent J Am Coll Cardiol 59 2012 1362 1370
24. V. Farooq, B.D. Gogas, and P.W. Serruys Restenosis: delineating the numerous causes of drug-eluting stent restenosis Circ Cardiovasc Interv 4 2011 195 205
25. J. Mehilli, R.A. Byrne, A. Wieczorek, R. Iijima, S. Schulz, and O. Bruskina Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis Eur Heart J 29 2008 1975 1982
26. R.A. Byrne, S. Kufner, K. Tiroch, S. Massberg, K.L. Laugwitz, and A. Birkmeier Randomised trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis: 2-year follow-up results Heart 95 2009 1489 1494
27. L. King, R.A. Byrne, J. Mehilli, A. Schomig, A. Kastrati, and J. Pache Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial Catheter Cardiovasc Interv 81 2013 E23 E28
28. N. Tada, R. Virmani, G. Grant, L. Bartlett, A. Black, and C. Clavijo Polymer-free biolimus a9-coated stent demonstrates more sustained intimal inhibition, improved healing, and reduced inflammation compared with a polymer-coated sirolimus-eluting cypher stent in a porcine model Circ Cardiovasc Interv 3 2010 174 183
29. E. Grube, R. Mueller, G. Schuler, K.E. Hauptmann, and J. Schofer TCT-46: Comparison of polymer-free BioFreedom stents with durable polymer Taxus Liberé stents: 3-year results from the BioFreedom first-in-man trial J Am Coll Cardiol 60 2012 B14
30. J.R. Costa Jr., A. Abizaid, R. Costa, F. Feres, L.F. Tanajura, and G. Maldonado 1-year results of the hydroxyapatite polymer-free sirolimus-eluting stent for the treatment of single de novo coronary lesions: the VESTASYNC I trial JACC Cardiovasc Interv 2 2009 422 427
31. J.R. Costa Jr. VESTAsync (MIV Therapeutics) program update Transcatheter Cardiovascular Therapeutics 2012
32. M. Yu, B. Xu, Y. Wu, H. Yan, J. Chen, and J. Qian TCT-229: First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in man BICARE trial J Am Coll Cardiol 58 20S1 2011 B62
33. S. Massberg, R.A. Byrne, A. Kastrati, S. Schulz, J. Pache, and J. Hausleiter Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the intracoronary stenting and angiographic results: test efficacy of sirolimus- and probucol-eluting versus zotarolimus-eluting stents (ISAR-TEST 5) trial Circulation 124 2011 624 632
34. D. Carrie, J. Berland, S. Verheye, K.E. Hauptmann, M. Vrolix, and R. Violini A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions J Am Coll Cardiol 59 2012 1371 1376
35. D. Carrie Cre8 program update Transcatheter Cardiovascular Therapeutics 2012
36. J. Aoki, P.W. Serruys, H. Van Beusekom, A.T. Ong, E.P. McFadden, and G. Sianos Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (healthy endothelial accelerated lining inhibits neointimal growth-first in man) registry J Am Coll Cardiol 45 2005 1574 1579 (Pubitemid 40704488)
37. M. Haude REMEDEE Combo (OrbusNeich) program update Transcatheter Cardiovascular Therapeutics 2012
38. A. Seth Nanoparticle based stents FOCUSnp program update Transcatheter Cardiovascular Therapeutics 2012
39. R.S. Stack, R.M. Califf, H.R. Phillips, D.B. Pryor, P.J. Quigley, and R.P. Bauman Interventional cardiac catheterization at Duke Medical Center Am J Cardiol 62 10 Pt 2 1988 F3 F24
40. a ed. 1994 Saunders Filadelfia 787 802
41. R. Waksman The disappearing stent: when plastic replaces metal Circulation 125 2012 2291 2294
42. W.J. Van der Giessen, A.M. Lincoff, R.S. Schwartz, H.M. Van Beusekom, P.W. Serruys, and D.R. Holmes Jr. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries Circulation 94 1996 1690 1697 (Pubitemid 26320276)
43. H. Tamai, K. Igaki, E. Kyo, K. Kosuga, A. Kawashima, and S. Matsui Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans Circulation 102 2000 399 404 (Pubitemid 30490677)
44. Y. Onuma, S. Garg, T. Okamura, J. Ligthart, R.J. Van Geuns, and P.J. De Feyter Ten-year follow-up of the IGAKI-TAMAI stent. A posthumous tribute to the scientific work of Dr Hideo Tamai EuroIntervention 5 Suppl F 2009 F109 F111
45. B. Heublein, R. Rohde, V. Kaese, M. Niemeyer, W. Hartung, and A. Haverich Biocorrosion of magnesium alloys: A new principle in cardiovascular implant technology? Heart 89 2003 651 656 (Pubitemid 36606211)
46. R. Waksman, R. Pakala, P.K. Kuchulakanti, R. Baffour, D. Hellinga, and R. Seabron Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries Catheter Cardiovasc Interv 68 2006 607 617 discussion 18-9 (Pubitemid 44546055)
47. R. Erbel, C. Di Mario, J. Bartunek, J. Bonnier, B. De Bruyne, and F.R. Eberli Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: A prospective, non-randomised multicentre trial Lancet 369 2007 1869 1875 (Pubitemid 46829357)
48. G. Ghimire, J. Spiro, R. Kharbanda, M. Roughton, P. Barlis, and M. Mason Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents EuroIntervention 4 2009 481 484
49. M. Haude, R. Erbel, P. Erne, S. Verheye, H. Degen, and D. Böse Safety and performance of the drug-eluting absorbable metal scaffold (DREAMS) in patients with de-novo coronary lesions: 12 month results of the prospective, multicentre, first-in-man BIOSOLVE-I trial Lancet. 12 2013 61765 61766 10.1016/S0140-6736
50. J.A. Ormiston, P.W. Serruys, E. Regar, D. Dudek, L. Thuesen, and M.W. Webster A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): A prospective open-label trial Lancet 371 2008 899 907 (Pubitemid 351384734)
51. P.W. Serruys, J.A. Ormiston, Y. Onuma, E. Regar, N. Gonzalo, and H.M. Garcia-Garcia A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods Lancet 373 2009 897 910
52. Y. Onuma, K. Nieman, M. Webster, L. Thuesen, D. Dudek, and J.A. Ormiston TCT-37: Five-year clinical outcomes and non-invasive angiographic imaging results with functional assessment after bioresorbable everolimus-eluting scaffold implantation in patients with de novo coronary artery disease J Am Coll Cardiol 60 2012 B11
53. S. Tanimoto, N. Bruining, R.T. Van Domburg, D. Rotger, P. Radeva, and J.M. Ligthart Late stent recoil of the bioabsorbable everolimus-eluting coronary stent and its relationship with plaque morphology J Am Coll Cardiol 52 2008 1616 1620
54. P.W. Serruys, Y. Onuma, D. Dudek, P.C. Smits, J. Koolen, and B. Chevalier Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes J Am Coll Cardiol 58 2011 1578 1588
55. J.A. Ormiston, P.W. Serruys, Y. Onuma, R.J. Van Geuns, B. De Bruyne, and D. Dudek First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: A multi-imaging modality study Circ Cardiovasc Interv 5 2012 620 632
56. Grube E. Bioabsorbable stent. The Boston Scientific and REVA technology. EuroPCR 2009. Barcelona; 2009.
57. R.A. Costa REVA ReZolve clinical program update Transcatheter Cardiovascular Therapeutics 2012
58. J. Yan, and V.D. Bhat Elixir Medical's bioresorbable drug eluting stent (BDES) programme: an overview EuroIntervention 5 Suppl F 2009 80 82
59. S. Verheye First-in-man results with a myolimus-eluting bioresorbable PLLA-based vascular scaffold Transcatheter Cardiovascular Therapeutics 2012
60. R. Jabara, N. Chronos, and K. Robinson Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating Catheter Cardiovasc Interv 72 2008 186 194
61. R. Jabara, N. Chronos, and K. Robinson Novel fully bioabsorbable salicylate-based sirolimus-eluting stent EuroIntervention 5 Suppl F 2009 F58 F64
62. J. Fajadet The ART stent: design and early first-in-man experiences Transcatheter Cardiovascular Therapeutics 2012
63. L. Shen, Q. Wang, Y. Wu, J. Xie, F. Zhang, and L. Ge Preliminary evaluation of fully bioabsorbable PLLA sirolimus eluting stents in a porcine model Chin J Intervent Cardiol 19 2009 301 305
64. L. Shen, Q. Wang, Y. Wu, J. Xie, and J. Ge Short-term effects of sirolimus eluting fully bioabsorbable polymeric coronary stents in a porcine model Transcatheter Cardiovascular Therapeutics 2011
65. J. Daemen, P. Wenaweser, K. Tsuchida, L. Abrecht, S. Vaina, and C. Morger Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study Lancet 369 2007 667 678 (Pubitemid 46281313)
66. C. Stettler, S. Wandel, S. Allemann, A. Kastrati, M.C. Morice, and A. Schomig Outcomes associated with drug-eluting and bare-metal stents: A collaborative network meta-analysis Lancet 370 2007 937 948 (Pubitemid 47393576)
67. P.W. Serruys, H.M. Garcia-Garcia, and Y. Onuma From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade? Eur Heart J 33 2012 16 25
68. S. Ramcharitar, H.M. Garcia-Garcia, G. Nakazawa, N. Kukreja, J. Ligthart, and R. Virmani Ultrasonic and pathological evidence of a neo-intimal plaque rupture in patients with bare metal stents EuroIntervention 3 2007 290 291
69. G. Nakazawa, F. Otsuka, M. Nakano, M. Vorpahl, S.K. Yazdani, and E. Ladich The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents J Am Coll Cardiol 57 2011 1314 1322
70. J.J. Wentzel, D.M. Whelan, W.J. Van der Giessen, H.M. Van Beusekom, I. Andhyiswara, and P.W. Serruys Coronary stent implantation changes 3-D vessel geometry and 3-D shear stress distribution J Biomech 33 2000 1287 1295 (Pubitemid 30427325)
71. J.J. Wentzel, F.J. Gijsen, J.C. Schuurbiers, A.F. Van der Steen, and P.W. Serruys The influence of shear stress on in-stent restenosis and thrombosis EuroIntervention 4 Suppl C 2008 C27 C32